Stock JAZZ JAZZ PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

News Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
108.3 USD -1.23% Intraday chart for Jazz Pharmaceuticals plc +1.14% -11.93%
Apr. 02 Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment MT
Apr. 02 Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
The PharmaMar Group presents financial results for the first quarter of 2024
AQ
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
PR
Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment
MT
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
CI
JPMorgan Raises Jazz Pharmaceuticals' Price Target to $190 From $170, Maintains Overweight Rating
MT
Piper Sandler Adjusts Price Target on Jazz Pharmaceuticals to $188 From $171, Maintains Overweight Rating
MT
Jazz Pharmaceuticals : Zanidatamab R&D Day
PU
Transcript : Jazz Pharmaceuticals plc - Special Call
Stifel Raises Jazz Pharmaceuticals' Price Target to $230 From $225, Maintains Buy Rating
MT
H.C. Wainwright Cuts Price Target on Jazz Pharmaceuticals to $200 From $204, Maintains Buy Rating
MT
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
PR
Transcript : Jazz Pharmaceuticals plc Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 02:00 PM
Agrify Corp Stock Presents Compelling Opportunity As Deal Flow Intensifies ($AGFY)
AQ
Transcript : Jazz Pharmaceuticals plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 10:30 AM
Jazz Pharmaceuticals : Corporate Overview
PU
UBS Adjusts Jazz Pharmaceuticals Price Target to $131 From $135, Maintains Neutral Rating
MT
Barclays Cuts Price Target on Jazz Pharmaceuticals to $230 From $235, Maintains Overweight Rating
MT
Needham Cuts Price Target on Jazz Pharmaceuticals to $220 From $225, Maintains Buy Rating
MT
Tranche Update on Jazz Pharmaceuticals plc's Equity Buyback Plan announced on November 8, 2016.
CI
Jazz: Q4 Earnings Snapshot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JAZZ Stock
  4. News Jazz Pharmaceuticals plc